Evolent Health Inc - Class A EVH Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$4.57 down $0.30, 6.16% at close Oct 16
Last close · Previous close $4.87
- Market cap
- $514.04MAt the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$4.49Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$4.57down $0.30, 6.16%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$4.87Oct 15
- Volume2.08MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.18MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.10 to $8.30; now $4.57
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
EVH beat the S&P 500 in 2 of 7 periods.
| Period | EVH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EVH: up 22.2% S&P 500: up 1.5% | EVH beat the S&P 500 by 20.7 percentage points Beat |
| 3M | EVH: down 19.4% S&P 500: up 1.9% | EVH trailed the S&P 500 by 21.3 percentage points Trailed |
| YTD | EVH: up 14.3% S&P 500: up 12.8% | EVH beat the S&P 500 by 1.5 percentage points Beat |
| 1Y | EVH: down 41.4% S&P 500: up 16.8% | EVH trailed the S&P 500 by 58.2 percentage points Trailed |
| Long term | ||
| 3Y | EVH: down 83.7% S&P 500: up 81.5% −45.4% vs +22.0% a year | EVH trailed the S&P 500 by 165.2 percentage points Trailed |
| 5Y | EVH: down 84.7% S&P 500: up 83.1% −31.3% vs +12.9% a year | EVH trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | EVH: down 81.0% S&P 500: up 319.6% −15.3% vs +15.4% a year | EVH trailed the S&P 500 by 400.6 percentage points Trailed |
$10,000 invested in EVH 10 years ago (Oct 14, 2016) would be worth about $1,903 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
EVH beat the S&P 500 in 2 of 7 periods.
| Period | EVH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EVH: up 22.2% S&P 500: up 1.2% | EVH beat the S&P 500 by 21.0 percentage points Beat |
| 3M | EVH: down 19.4% S&P 500: up 1.7% | EVH trailed the S&P 500 by 21.1 percentage points Trailed |
| YTD | EVH: up 14.3% S&P 500: up 11.9% | EVH beat the S&P 500 by 2.4 percentage points Beat |
| 1Y | EVH: down 41.4% S&P 500: up 15.5% | EVH trailed the S&P 500 by 56.9 percentage points Trailed |
| Long term | ||
| 3Y | EVH: down 83.7% S&P 500: up 75.0% −45.4% vs +20.5% a year | EVH trailed the S&P 500 by 158.7 percentage points Trailed |
| 5Y | EVH: down 84.7% S&P 500: up 71.2% −31.3% vs +11.4% a year | EVH trailed the S&P 500 by 155.9 percentage points Trailed |
| 10Y | EVH: down 81.0% S&P 500: up 258.1% −15.3% vs +13.6% a year | EVH trailed the S&P 500 by 339.1 percentage points Trailed |
$10,000 invested in EVH 10 years ago (Oct 14, 2016) would be worth about $1,903 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$39.74
Closing high on . Now 88.5% below that record.
Split-adjusted daily closes since Jun 5, 2015.
Stock splits
EVH hasn’t split since its price history begins in 2015.
Valuation
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$4.49 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 0.2×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.3×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 22.50%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $1.34BAt the Oct 16 close
What it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own EVH DCF in Excel. Value Evolent Health with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $2.10Bdown 4.5%
- Net income
- −$504.99M
- Diluted EPS
- −$4.49
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $621.40M | −$23.14M | −$0.27 |
| Q4 FY24 (Dec 31, 2024) | $646.54M | −$22.80M | −$0.26 |
| Q1 FY25 (Mar 31, 2025) | $483.65M | −$64.62M | −$0.63 |
| Q2 FY25 (Jun 30, 2025) | $444.33M | −$19.90M | −$0.44 |
| Q3 FY25 (Sep 30, 2025) | $479.53M | −$20.86M | −$0.24 |
| Q4 FY25 (Dec 31, 2025) | $468.72M | −$429.13M | −$3.76 |
| Q1 FY26 (Mar 31, 2026) | $496.25M | −$26.63M | −$0.24 |
| Q2 FY26 (Jun 30, 2026) | $652.52M | −$28.36M | −$0.25 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $907.96M | −$37.60M | −$0.44 |
| FY22 (Dec 31, 2022) | $1.35B | −$19.16M | −$0.20 |
| FY23 (Dec 31, 2023) | $1.96B | −$113.04M | −$1.28 |
| FY24 (Dec 31, 2024) | $2.55B | −$61.62M | −$0.81 |
| FY25 (Dec 31, 2025) | $1.88B | −$534.51M | −$5.07 |
Margins
- Gross 17.2%
- Operating −20.2%
- Net −24.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $115.65MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$54.32MLast 12 months
- Capital spending$61.33MLast 12 months
- 5.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $40.00MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$40.00MLast 12 months
35% of free cash flow
Balance sheet
- $150.23MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$970.43MAs of Jun 30, 2026
- Net debt$820.20MAs of Jun 30, 2026
- 1.24As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 2.53As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −99.2%Last 12 months
Over the last 12 months, Evolent Health lost money: its net loss was 99.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −24.6%Last 12 months
Over the last 12 months, Evolent Health’s net loss was 24.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Evolent Health Inc - Class A
Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- Virginia, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
EVH news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
EVH stock FAQ
What is EVH stock’s price today?
Evolent Health (EVH) traded at $4.57 at the close on , down $0.30 (6.16%) from the previous close of $4.87. Over the past 52 weeks it has traded between $2.10 and $8.30.
If you invested $1,000 in EVH 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in EVH on would be worth about $190 at the close on , a total return of −81.0%. The same $1,000 would be worth $153 if invested five years ago and $586 if invested one year ago. Past performance doesn’t predict future returns.
What is Evolent Health’s market cap?
Evolent Health’s market capitalization is about $514.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $4.57 (how market cap works). Evolent Health reported 112.48M shares outstanding at the end of its latest quarter ().
What is EVH’s P/E ratio?
EVH’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$4.49).
How much revenue does Evolent Health make?
Evolent Health reported $2.1 billion of revenue over the four quarters to , down 4.5% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $652.5 million, up 46.9% from a year earlier.
Is Evolent Health profitable?
Not over the four quarters to . Evolent Health reported a net loss of $505.0 million across those four quarters on $2.1 billion of revenue.
What are EVH’s earnings per share?
EVH’s diluted earnings per share were −$4.49 over the four quarters to , compared with −$1.60 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.25 per share, against −$0.44 a year earlier (how EPS works).
Does EVH pay a dividend?
Evolent Health hasn’t paid a dividend in the last twelve months.
What is EVH’s 52-week high and low?
Over the past 52 weeks EVH has traded as low as $2.10 and as high as $8.30. At $4.57 at the close on , it is 44.9% below that high and 118.1% above the low.
What is EVH’s all-time high?
EVH’s highest closing price was $39.74 on , adjusted for stock splits. At $4.57 at the close on , it is 88.5% below that record.
Has EVH stock ever split?
No. EVH hasn’t split since its price history begins in 2015.
How has EVH stock performed?
Including dividends and measured to the close on , EVH has returned +14.3% so far this year and −41.4% over the past year, and −84.7% over five years (−31.3% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Evolent Health in?
Evolent Health is in the Healthcare sector and the Health Information Services industry, and is headquartered in Virginia, USA.
What exchange does EVH trade on?
Evolent Health trades on the NYSE under the ticker symbol EVH. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.